Gina Mazzariello sold $246k of AMLX
Chief Legal Officer at Amylyx Pharmaceuticals, Inc.. 30,000 shares at an average of $8.20, traded Aug 12, 2025, filed Aug 14, 2025.
Score components
- +15RoleOfficer
- +13Trade size$246k at market
- +5Share of holdings soldSold 16% of holdings
- 0ClusterNo other insider selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-25-108912, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 12, 2025 | SOpen-market sale Common Stock10b5-1 | -15,000 | $8.07 | $121k | 171,969 | Aug 14, 2025 |
| Aug 13, 2025 | SOpen-market sale Common Stock10b5-1 | -15,000 | $8.34 | $125k | 156,969 | Aug 14, 2025 |
Related signals
Other insiders at Amylyx Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 18Weak | Amylyx Pharmaceuticals, Inc. | George M Milne Jr director | $831k 30,000 shares | -4% | |
| 65Notable | Amylyx Pharmaceuticals, Inc. | Justin B. Klee Co-Chief Executive Officer | $980k 30,464 shares | -1% | |
| 65Notable | Amylyx Pharmaceuticals, Inc. | Joshua B Cohen Co-Chief Executive Officer | $981k 30,464 shares | -1% | |
| 44Moderate | Amylyx Pharmaceuticals, Inc. | Gina Mazzariello Chief Legal Officer | $310k 9,536 shares | -5% | |
| 52Moderate | Amylyx Pharmaceuticals, Inc. | James M Frates Chief Financial Officer | $350k 10,810 shares | -4% | |
| 44Moderate | Amylyx Pharmaceuticals, Inc. | Camille L Bedrosian Chief Medical Officer | $325k 10,028 shares | -3% | |
| 32Weak | AMLXbuy Amylyx Pharmaceuticals, Inc. | Karen Firestone director | $101k 8,100 shares | +15% | |
| 25Weak | AMLXsell Amylyx Pharmaceuticals, Inc. | Camille L Bedrosian Chief Medical Officer | $94k 6,580 shares | -4% | |
| 42Moderate | Amylyx Pharmaceuticals, Inc. | Camille L Bedrosian Chief Medical Officer | $176k 12,039 shares | -6% | |
| 57Moderate | Amylyx Pharmaceuticals, Inc. | Joshua B Cohen Co-Chief Executive Officer | $429k 29,933 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.